Crinetics Pharmaceuticals, Inc. (CRNX) Shareholders & Insider Trades
Crinetics Pharmaceuticals shareholders at a glance
The largest holder of Crinetics Pharmaceuticals stock is Fidelity Management & Research Co. LLC, with 15.8 million shares (16.73% of the company), worth about $611.00 million as of May 19, 2026. The 10 largest holders together own 82.0%.
In Q2 2026, 276 institutional holdings reports listed shares worth $4.73 billion.
Insiders reported 39 transactions in the last two years: 16 sales worth $8.43 million and no purchases. The newest one on file is from November 3, 2025 (Pizzuti Dana J, Officer).
Major holders as of May 19, 2026; quarterly totals from institutional holdings reports (latest Q2 2026); insider transactions on file through November 3, 2025.
Crinetics Pharmaceuticals, Inc.
Shareholders Summary
2026Q2
Ownership by Type
Geographic Distribution
Largest Crinetics Pharmaceuticals shareholders
| Holder | Shares | % of company | Value |
|---|---|---|---|
| Fidelity Management & Research Co. LLC | 15.8 million | 16.73% | $611.0M |
| Farallon Capital Management LLC | 8.3 million | 8.85% | $323.0M |
| Wellington Management Co. LLP | 8.2 million | 8.66% | $316.0M |
| Wellington Trust Co., NA | 8.2 million | 8.66% | $316.0M |
| BlackRock Advisors LLC | 7.9 million | 8.39% | $306.0M |
| Driehaus Capital Management LLC | 6.4 million | 6.79% | $248.0M |
| Driehaus Capital Management LLC | 6.4 million | 6.79% | $248.0M |
| Vanguard Capital Management LLC | 5.4 million | 5.78% | $211.0M |
| T. Rowe Price International Ltd. | 5.4 million | 5.69% | $208.0M |
| T. Rowe Price Associates, Inc. (IM) | 5.4 million | 5.69% | $208.0M |
As of May 19, 2026.
Crinetics Pharmaceuticals institutional holdings by quarter
| Quarter | Reports | Shares | Value |
|---|---|---|---|
| Q2 2026 | 276 | – | $4.7B |
| Q1 2026 | 254 | – | $4.5B |
| Q4 2025 | 257 | – | $5.2B |
| Q3 2025 | 239 | 109.0 million | $4.5B |
| Q2 2025 | 232 | 105.0 million | $3.0B |
| Q1 2025 | 238 | 102.0 million | $3.4B |
| Q4 2024 | 257 | 99.7 million | $5.1B |
| Q3 2024 | 244 | 84.8 million | $4.3B |
Shares and value held by institutions that file quarterly holdings reports (options not included).
Crinetics Pharmaceuticals insider trades
| Insider | Date | Title | Transaction | Value |
|---|---|---|---|---|
| Pizzuti Dana J | Nov 3, 2025 | Officer | Conversion of Exercise of derivative security at price 16.89 per share. | $84,450 |
| Pizzuti Dana J | Nov 3, 2025 | Officer | Sale at price 42.65 - 43.27 per share. | $213,312 |
| Pizzuti Dana J | Oct 1, 2025 | Officer | Conversion of Exercise of derivative security at price 16.89 per share. | $84,450 |
| Pizzuti Dana J | Oct 1, 2025 | Officer | Sale at price 41.81 per share. | $209,050 |
| Fust Matthew K. | Sep 26, 2025 | Director | Conversion of Exercise of derivative security at price 1.91 per share. | $19,100 |
| Struthers Richard Scott | Sep 26, 2025 | Chief Executive Officer | Sale at price 45.00 per share. | $180,000 |
| Fust Matthew K. | Sep 26, 2025 | Director | Sale at price 44.75 per share. | $716,000 |
| Pizzuti Dana J | Sep 2, 2025 | Officer | Conversion of Exercise of derivative security at price 16.89 per share. | $84,450 |
| Pizzuti Dana J | Sep 2, 2025 | Officer | Sale at price 32.10 per share. | $160,500 |
| Pizzuti Dana J | Aug 22, 2025 | Officer | Conversion of Exercise of derivative security at price 16.89 per share. | $506,700 |
| Pizzuti Dana J | Aug 22, 2025 | Officer | Sale at price 30.43 per share. | $912,900 |
| Pizzuti Dana J | Aug 20, 2025 | Officer | Sale at price 29.18 per share. | $189,437 |
Newest 12 of 39 insider transactions in the last two years.
Questions and answers
Who owns the most Crinetics Pharmaceuticals stock?
Fidelity Management & Research Co. LLC, with 16.73% of the company (as of May 19, 2026). Next: Farallon Capital Management LLC (8.85%) and Wellington Management Co. LLP (8.66%).
How many institutions own Crinetics Pharmaceuticals stock?
276 institutional holdings reports listed Crinetics Pharmaceuticals shares in Q2 2026 worth $4.73 billion.
Are Crinetics Pharmaceuticals insiders buying or selling the stock?
In the last two years insiders reported 16 sales and no purchases (39 transactions in all); the newest on file is from November 3, 2025.
